Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pharming Group N.V (PHAR) Gross Margin: 2020-2025

Historic Gross Margin for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to 92.73%.

  • Pharming Group N.V's Gross Margin rose 184.00% to 92.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 148.27%, marking a year-over-year increase of 5887.00%. This contributed to the annual value of 88.09% for FY2024, which is 163.00% down from last year.
  • Pharming Group N.V's Gross Margin amounted to 92.73% in Q3 2025, which was up 100.59% from -15,735.60% recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Gross Margin ranged from a high of 95.61% in Q3 2022 and a low of -15,735.60% during Q2 2025.
  • For the 3-year period, Pharming Group N.V's Gross Margin averaged around -1,493.22%, with its median value being 89.37% (2023).
  • In the last 5 years, Pharming Group N.V's Gross Margin soared by 578bps in 2022 and then tumbled by 1,582,483bps in 2025.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Gross Margin stood at 89.37% in 2021, then crashed by 85bps to 88.52% in 2022, then spiked by 272bps to 91.24% in 2023, then plummeted by 441bps to 86.82% in 2024, then surged by 184bps to 92.73% in 2025.
  • Its Gross Margin was 92.73% in Q3 2025, compared to -15,735.60% in Q2 2025 and 86.82% in Q4 2024.